Načítá se...
Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by K(ATP) channel overactivity
Cantu syndrome (CS) is a complex disorder caused by gain-of-function (GoF) mutations in ABCC9 and KCNJ8, which encode the SUR2 and Kir6.1 subunits, respectively, of vascular smooth muscle (VSM) K(ATP) channels. CS includes dilated vasculature, marked cardiac hypertrophy, and other cardiovascular abn...
Uloženo v:
| Vydáno v: | J Clin Invest |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7269588/ https://ncbi.nlm.nih.gov/pubmed/31821173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI130571 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|